1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 234 results for "Multiple Myeloma (MM)".

Thumbnail for Real-World Outcomes of Primary and Secondary Plasma Cell Leukemia in the Era of CAR-T and Bispecific Antibody Therapy: A Single-Center Experience

MM - 1031

Real-World Outcomes of Primary and Secondary Plasma Cell Leukemia in the Era of CAR-T and Bispecific Antibody Therapy: A Single-Center Experience

Abat Khan

Poster Presenter: Abat Khan

$Thumbnail for Efficacy and Safety of Chimeric Antigen Receptor T-cell (CAR-T) Therapy Against Standard Regimen in Relapsed/Refractory Multiple Myeloma: A Meta-Analysis$

MM - 1033

Efficacy and Safety of Chimeric Antigen Receptor T-cell (CAR-T) Therapy Against Standard Regimen in Relapsed/Refractory Multiple Myeloma: A Meta-Analysis

Maryam Maqsood

Poster Presenter: Maryam Maqsood

SOHO 2026 Annual Meeting

Topics

Real-World Outcomes of Primary and Secondary Plasma Cell Leukemia in the Era of CAR-T and Bispecific Antibody Therapy: A Single-Center Experience

Efficacy and Safety of Chimeric Antigen Receptor T-cell (CAR-T) Therapy Against Standard Regimen in Relapsed/Refractory Multiple Myeloma: A Meta-Analysis

Clinical Investigators' Selection of Induction and Maintenance Therapy for Patients With Newly Diagnosed Multiple Myeloma Eligible and Ineligible for Transplant

Target-Specific Toxicity Phenotypes of BCMA- vs GPRC5D-Directed Bispecific Antibodies in Multiple Myeloma: A FAERS Analysis

OPTec/OPTal: A Phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

GLP-1 Receptor Agonists and Venous Thromboembolism Risk in Multiple Myeloma

T-Cell Exhaustion-Based Transcriptomic Signature Predicts Multiple Myeloma Survival and Reveals Montelukast as an Immunomodulatory Repositioning Candidate

Therapeutic Targeting of SETD8 Suppresses Multiple Myeloma Growth Through the IRF4/MYC Axis

Trial in Progress: QUINTESSENTIAL-2, a Phase 3 Study of Arlocabtagene Autoleucel vs Standard of Care in Adult Patients With Relapsed/Refractory Multiple Myeloma Exposed to Lenalidomide